KRAS and colon carcinoma: We observed that Sorafenib inhibited AKT activity only in CaCO2 colon carcinoma cells that are BRAF and KRAS wildtype, and led to an increase in AKT activity in the other cell lines, which had mutations in either KRAS or BRAF.